myNEURVA

myNEURVA is a neurotechnology company based in Charlottesville, Virginia, developing a clinician-guided neurofeedback platform designed to support cognitive rehabilitation in patients recovering from post-concussion syndrome and traumatic brain injury. The company's cloud-based system connects patients directly with remote neurofeedback therapists, enabling structured, personalized treatment to be delivered outside of traditional clinical settings. By digitizing and scaling the neurofeedback therapy model, myNEURVA removes geographic and logistical barriers that have historically limited patient access to this form of neurorehabilitation. Their approach combines established neurofeedback science with modern telehealth infrastructure to create a reproducible, therapist-supervised care pathway.

myNEURVA has secured $8 million in Series A funding, signaling meaningful investor confidence in both their technology platform and the broader clinical opportunity within acquired brain injury rehabilitation. The company is positioned at the intersection of digital health and neuroscience, targeting a patient population that remains significantly underserved by conventional treatment options. Post-concussion syndrome and TBI recovery represent a large and growing unmet need, particularly among athletes, military veterans, and survivors of accidents or falls. By building a scalable, remote-delivery model, myNEURVA is establishing early infrastructure in a market that has lacked standardized, accessible therapeutic options.

myNEURVA represents an important development for the neurotech industry because it moves neurofeedback from a largely fragmented, clinic-dependent practice toward a structured, technology-enabled care model with the potential for clinical validation at scale. Their platform demonstrates how neuromodulation and brain-based therapies can be integrated with digital health delivery systems to reach broader patient populations. As regulatory and reimbursement pathways for digital therapeutics continue to evolve, companies like myNEURVA are helping define what evidence-based, remotely delivered neurotechnology looks like in practice. Their work contributes to the wider legitimization of neurofeedback as a credible therapeutic modality within mainstream healthcare.